• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Copley Scientific banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Moat Biotechnology raises $6.5 million for development of intranasal/inhaled COVID-19 vaccine

Moat Biotechnology (MoatBio), a spin-out from Tetherex Pharmaceuticals, announced that it has closed a funding round of more than $6.5 million following an initial funding led by Cortado Ventures in September 2022. The company says that it intends to use the proceeds for continued development of an inhaled/intranasal COVID-19 vaccine based on the SC-AdVax single-cycle adenovirus vaccine platform licensed from the Mayo Clinic. MoatBio reported positive interim results from a Phase 1 trial of its initial intranasal vaccine in the September 2022 announcement, and the company says that it intends to do further Phase 1 testing that vaccine and plans to develop additional vaccines based on SC-AdVax.

MoatBio CEO Scott Rollins commented, “Respiratory viruses like SARS-CoV-2 enter through the nasal passages, and if the viruses are encountered there, then we can significantly reduce their ability to replicate systemically within the body, where more serious viral morbidities occur. This first close of funding allows us to continue our important Phase 1 trial research. The ability to vaccinate individuals through needle-free delivery, including intranasal/inhaled or oral administration, not only for COVID-19, but for many pathogens, should be a game changer.”

President and Chief Operating Officer Russell Rother said, “Our goal is to prevent or reduce the morbidity and mortality for multiple serious infectious diseases that are currently underserved by vaccines and other treatments. Whether it is COVID-19 or another highly infectious disease like influenza or Ebola, we are confident that with the SC-AdVax technology, we can provide a new level of protection against this and future pandemics or epidemics while offering a more palatable and accessible mode of administration.”

Read the Moat Biotechnology press release.

Share

published on June 14, 2023

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Solstice Air banner
    © 2025 OINDPnews